Lenalidomide versus methotrexate for stubborn lupus skin disease
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This study tests whether the drug lenalidomide works better than methotrexate for people with lupus that mainly affects the skin and is hard to treat. Both drugs are taken by mouth and have been used for other conditions, but this trial compares them directly to see which helps clear the skin rash more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- Your lupus skin disease must be confirmed by a skin biopsy (a small sample of skin taken for testing).
- Your skin disease must be active, with a severity score of 8 or higher on the CLASI scale.
- Standard treatments (like antimalarial drugs) must not have worked for you, or you must have had to stop them because of side effects.
- You cannot have severe lupus affecting your kidneys, brain, or blood cells that requires strong immune-suppressing medications.
- You must not be pregnant, planning to become pregnant, or breastfeeding during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if quinacrine, an oral drug, improves skin rashes caused by lupus. You may be eligible if you have a type of skin lupus called SCLE or DLE that hasn't improved with standard treatments like steroids or hydroxychloroquine.
This early-phase study tests a new medicine called HC022 for people with lupus (SLE) or lupus skin disease (CLE). The goal is to check its safety and see if it helps reduce symptoms, and the study will monitor you closely.
This trial tests an experimental drug called ICP-488 for people with active cutaneous lupus erythematosus (CLE), a type of lupus that affects the skin. It aims to see if the drug can reduce skin inflammation and improve symptoms.
This study tests an experimental medicine called VENT-03 to see if it can improve skin lupus symptoms in adults. It compares VENT-03 against a placebo (a pill with no active drug) and includes a longer-term option where everyone can get the real drug. The goal is to find a new treatment for people whose lupus affects their skin.
This trial tests two new drugs, BCD-256-1 and divozilimab, for people with systemic lupus erythematosus (SLE) who have active skin symptoms not controlled by current treatments. The goal is to see if they are safe and how the body processes them.
This study tests the drug methotrexate as a treatment for severe vulvar lichen sclerosus that has not responded to strong steroid creams. It aims to see if methotrexate can reduce symptoms and prevent further scarring.
Hear when a new Cutaneous Lupus Erythematosus (CLE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.